Increased p38 mitogen-activated protein kinase (MAPK) in response to stress stimuli, including hyperglycemia, contributes to diabetic somatic neuropathy. However, effects on autonomic nerve and vascular function have not been determined. The aim of this study was to investigate the effects of the p38 MAPK inhibitor, LY2161793, on penile neurovascular function in streptozotocin-induced diabetic mice. Diabetes duration was 6 weeks and intervention LY2161793 treatment was given for the final 2 weeks. In vitro measurements on phenylephrine-precontracted corpus cavernosum revealed a 32% reduction in maximum nitrergic nerve-mediated relaxation with diabetes that was 74% corrected by LY2161793 treatment. Maximum nitric oxide-mediated endothelium-dependent relaxation to acetylcholine was 42% attenuated by diabetes and 88% restored by LY2161793. Moreover, treatment partially corrected a diabetic deficit in endothelium-independent relaxation to a nitric oxide donor. Thus, p38 MAPK inhibition corrects nitric oxide-dependent indices of diabetic erectile autonomic neuropathy and vasculopathy, a therapeutic approach potentially worthy of consideration for clinical trials.
Introduction
The p38 mitogen-activated protein (MAP) kinase (MAPK) is a member of the superfamily of MAP serine/threonine protein kinases that also includes extracellular signal-regulated kinase (ERK) and c-Jun NH 2 -terminal kinase (JNK). Together, they drive a host of cellular responses including survival, growth and apoptosis, via upregulation of numerous transcription factors. Activation of p38 MAPK (and JNK) can be triggered by cellular stresses such as hyperglycemia and oxidative stress, which play an important role in the development of diabetic complications. [1] [2] [3] Nephropathy, neuropathy and retinopathy are common complications of long-term diabetes. The vascular component of the etiology of diabetic neuropathy is well established; reduced endoneurial blood flow accompanies deficits in peripheral nerve conduction.
1 Penile erection involves neurologically mediated relaxation of corpus cavernosum vasculature and smooth muscle, with associated restriction of venous outflow. 4 Sacral parasympathetic nerves supply vasodilator nitric oxide directly, and indirectly via the endothelium, during this process. Nitric oxide-dependent deficits in cavernosum smooth muscle relaxation are evident in diabetic animals and man. [5] [6] [7] [8] Inhibition of p38 MAPK prevents somatic neuropathy in experimental diabetes including nerve conduction velocity deficits, tactile allodynia and inflammatory pain. 9, 10 Nonetheless, a potential role for p38 MAPK in autonomic nitrergic nerve dysfunction has not been studied. For endothelial cells, p38 MAPK is elevated during incubation at high glucose concentrations, and p38 MAPK inhibition prevents cytoskeletal rearrangement in response to shear stress. 11, 12 However, any potential consequences for endothelial vasodilator function in diabetes have not been determined. Thus, the aim was to assess the effects of the p38 MAPK inhibitor, LY2161793, on neurovascular function in corpus cavernosum from diabetic mice.
Materials and methods

Animals
Male MF1 mice were purchased from Harlan (Bicester, Oxford, UK) at 3 months and were aged between 6 and 8 months on the day of experimentation. All mice received standard laboratory chow and had access to water ad libitum. Experiments were performed in accordance with regulations specified by the UK 'Animal (Scientific Procedures) Act, 1986'. Unless otherwise stated, chemicals were obtained from Sigma (Poole, Dorset, UK).
Diabetes induction, treatment and anesthesia
Diabetes was induced by 125 mg/kg intraperitoneal (i.p.) streptozotocin dissolved in sterile 154 mmol/l saline solution; duration was 6 weeks. Diabetic mice were weighed daily and were rejected if nonfasting blood glucose levels, measured by a glucose meter (Ascensia Esprit 2, Bayer Diagnostics, Dublin, Ireland) on samples taken from the heart, were less than 20 mmol/l on the day of experimentation. In addition to untreated nondiabetic and diabetic control groups, one group of diabetic mice received intervention LY2161793 treatment (Eli-Lilly Inc., Indianapolis, IN, USA) at a dose of 20 mg/kg/day as a dietary supplement for 2 weeks, following 4 weeks of untreated diabetes. This level of p38 MAPK inhibition has previously been shown to prevent somatic nerve conduction velocity deficits in diabetic rats and counteract collagen-induced arthritic changes in nondiabetic rats. 9, 13 LY2161793 is an imidazole-based inhibitor that is specific for the a and b isoforms of MAPK. 13 In vitro selectivity studies against a panel of kinases did not reveal any inhibitory action on p38 MAPK gamma, MAPKactivated protein kinase 2, transforming growth factor-b receptor 1, calmodulin-dependent kinase II, cAMP-dependent protein kinase, cyclin E-cyclindependent kinase 2, phosphatidylinositol 3 kinase (PI3K) and vascular endothelial growth factor receptor 2. 13 Notably, there was no direct effect on protein kinase C b, which has been strongly implicated in diabetic vascular complications, including mouse corpus cavernosum dysfunction. 14, 15 Corpus cavernosum studies Mice were anesthetized by 5% isoflurane in air and 0.1 ml of 10% urethane in 154 mmol/l saline/10 g body weight i.p. and exsanguinated following tissue removal. The penis was excised at its base and the glans penis and connective tissues surrounding the shaft were removed. The cavernosa were then separated and each strip of tissue was mounted in a 10 ml organ bath containing modified KrebsRinger solution (144 NaCl, 5 KCl, 1.1 MgSO 4 , 25 NaHCO 3 , 1.1 NaH 2 PO 4 , 1.25 CaCl 2 and 5.5 glucose (in mmol/l)) at 371C (pH 7.35) and gassed with a 95% O 2 :5% CO 2 mixture. Isometric tension was monitored and resting tension was set at 0.5 g; tissues were equilibrated for 45 min with frequent changes of the bathing media. Cumulative concentration-response curves to the a 1 adrenoceptor agonist, phenylephrine, and the endothelium-independent nitric oxide donor sodium nitroprusside (following B80% maximal phenylephrine contraction) were determined. For endothelium-dependent relaxation to acetylcholine (against phenylephrine precontraction), noncumulative concentrationresponse curves were determined because of the transient nature of responses to this drug. Transmural electrical field stimulation was delivered via platinum wire electrodes (duration 30s; 2-30 Hz; 5 ms pulses; 10 V). Nonadrenergic, noncholinergic (NANC)-transmitter-mediated relaxations were examined in response to electrical stimulation against phenylephrine precontraction in the presence of the muscarinic antagonist atropine (1 mmol/l) and adrenergic blocker guanethidine (4 mmol/l). At the end of experiments, tissues were lightly patted dry and weighed.
Statistical analysis
Data are expressed as means7s.e.m. They were subjected to Bartlett's test for homogeneity of variances before one-way analysis of variance (ANOVA). Where significance was reached (Po0.05), between-group differences were established using the Newman-Keuls multiple comparison test. Otherwise, data were analyzed by Kruskal-Wallis nonparametric one-way ANOVA and Dunn's multiple comparison test. Concentration-response curves were fitted by sigmoid curves using the least-squares method to calculate EC 50 . Whole-curve differences were tested using two-way ANOVA. All calculations were determined by a standard statistical software package (Prism4, Graphpad, San Diego, CA, USA).
Results
Plasma glucose concentrations and body and corpus cavernosum weights Diabetes caused an approximate three-fold increase in plasma glucose concentrations (Po0.001) and reduced body weights by 10-14% (Po0.001; Table 1); these changes were unaffected by intervention LY2161793 treatment. However, cavernosum tissue weights did not differ significantly between Diabetic mouse cavernosum and p38 MAPK MR Nangle et al groups; thus, weights were 9.770.3 mg, n ¼ 13, and 10.170.3 mg, n ¼ 12, for nondiabetic and diabetic control, and 10.070.4 mg, n ¼ 9, for LY2161793-treated diabetic cavernosum, respectively.
Corpus cavernosum study
Electrical stimulation of corpus cavernosum elicited frequency-dependent contractions mediated by adrenergic nerves (guanethidine and tetrodotoxin sensitive); there were no significant differences between groups (Figure 1a) . Thus, maximum contractions (at 30 Hz) were 0.09570.010 and 0.08770.009 g for nondiabetic and diabetic controls, and 0.10070.009 g for LY2161793-treated diabetic tissue, respectively.
Electrical stimulation following phenylephrine precontraction in the presence of 1 mmol/l atropine and 4 mmol/l guanethidine produced frequencydependent relaxation mediated by nitrergic nerves (L-NNA sensitive; Figure 1b) . Maximum relaxation at 20 Hz was reduced by approximately 32% with diabetes compared to nondiabetic cavernosum (49.173.9 vs 72.174.1%, Po0.01). This deficit was 74% corrected by LY2161793 treatment (66.275.4%, Po0.05) to the extent that the relaxation did not significantly differ from the nondiabetic control group.
Maximum endothelium-dependent relaxation to acetylcholine (Figure 2a) Following phenylephrine precontraction, diabetes tended to reduce maximum endothelium-independent relaxation and sensitivity to sodium nitroprusside (Figure 2b) . Thus, percentage relaxation and (Àlog) EC 50 values were 68.673.6% and 6.5870.06 mol/l for nondiabetic control; 55.772.8% and 6.3670.05 mol/l for diabetic control; and 59.276.0% and 6.5270.11 mol/l for LY2161793-treated diabetic cavernosum, respectively. Two-way ANOVA revealed a significant whole-curve diabetic deficit against the nondiabetic control group (Po0.001). The whole-curve deficit was partially corrected by LY2161793 treatment (Po0.01); however, relaxation remained 
Discussion
In agreement with previous reports for mice, streptozotocin-diabetes blunted nitric oxide-dependent corpus cavernosum smooth muscle relaxation in response to NANC neurotransmission and muscarinic agonism. 6, 7 This is the first study to demonstrate that chronic p38 MAPK inhibition can reverse these deficits, despite only partial recovery of reduced smooth muscle responsiveness to nitric oxide.
In diabetic patients, the ability of vascular smooth muscle to relax to nitric oxide donors is reported to be either unaltered or depressed. 16, 17 Similar discrepancies are observed in the experimental literature. For example, responsiveness of penile tissue to the nitric oxide donor, sodium nitroprusside, is often unaffected by diabetes; however, decreased relaxation has also been observed. 7, [18] [19] [20] One group found that the defect was normalized in diabetic rats when the tension readings were expressed relative to tissue weight, to take account of differing tissue weights. 21 However, in that study diabetes was induced in immature animals and the metabolic changes could have altered the normal growth and maturation of corpus cavernosum. This would affect interpretation, and it is not clear whether agematched controls are appropriate for comparison in this study, as opposed to dietary restriction to produce age-and weight-matched controls. In contrast, when diabetes was induced in mature rats, there is no reduction in cavernosum weight and diabetic defects in endothelium-dependent but not endothelium-independent relaxation were observed. 18 In the present study, using mature mice, there was a modest body weight loss with diabetes, but no effect on cavernosum weight so the argument does not apply.
The discrepancy in the mouse literature may be strain related. Relaxation to nitroprusside was unaltered in diabetic C57 mouse cavernosum; however, reduced responsiveness was previously reported for the MF1 model. 6, 7, 19 Cultured vascular smooth muscle cells develop increased levels of phosphorylated p38 MAPK in response to high glucose, as do aortas from diabetic rats. 22 Thus, activation of p38 MAPK may play a role in situations where smooth muscle responsiveness to nitric oxide is reduced as its inhibition partially reversed the deficit in the present study. Overall, the severity and progression of vascular damage in chronic diabetes, particularly in association with elevated plasma lipids, may explain differences in responsiveness to nitric oxide donors noted in man. 23 Endothelium-dependent nitric oxide-mediated relaxations to agonists such as acetylcholine are depressed by diabetes in multiple vascular tissues, including cavernosum. 8 Endothelial function is particularly susceptible to diabetic aberrations such as hyperglycemia, increased oxidative stress and Diabetic mouse cavernosum and p38 MAPK MR Nangle et al altered lipid profiles. 24 Nitric oxide is rapidly scavenged by superoxide anion, forming peroxynitrite that together with reduced availability of nitric oxide can have deleterious consequences on vascular function. 25 The activation of p38 MAPK is a stress-sensitive mechanism, triggered by hyperglycemia and oxidative stress. 2 Like vascular smooth muscle cells, cultured endothelial cells show increased levels of phosphorylated p38 MAPK in response to hyperglycemia; this process has been linked to the pathogenesis of vasculopathy via increased endothelial cell proliferation, monocyte adhesion and lesion formation. 11, 22, 26, 27 In cavernosum from impotent men, raised MAPK 1/2 (ERK 1/2) levels inhibit the activity of endothelial nitric oxide synthase. 28 MAPK 1/2 (ERK 1/2) and p38 MAPK have antagonistic roles in the regulation of endothelial function and there is a recognized crosstalk between individual MAPK pathways whereby activation of one can influence another. 29 Similarly, the importance of the PI3K/Akt pathway has been demonstrated for the maintenance of penile erection in mice via phosphorylation and activation of endothelial nitric oxide synthase. 30 The detailed mechanism whereby inhibition of p38 MAPK in diabetes restores endothelial nitric oxide synthase-dependent function is not known. In particular, the effects of diabetes on the expression and possible crosstalk between MAPKs and other signaling pathways in erectile tissue are not known in detail and could provide a novel avenue for further research. However, it is also possible that nitric oxide action was improved by LY2161793 treatment through effects independent of nitric oxide synthase expression or activation. For example, management of reactive oxygen species in diabetes augments nitric oxide bioavailability. 31, 32 Contractile responses to exogenous phenylephrine were unaltered either by diabetes or LY2161793, suggesting that the beneficial effects of treatment on vasodilator function were not the result of any changes in the level of constriction against which relaxations were measured. Similarly, smooth muscle contractions achieved via noradrenergic nerve stimulation were not altered by diabetes or p38 MAPK inhibition. Thus, short-term diabetes does not appear to alter sympathetic noradrenergic autonomic nerve function or postsynaptic contractile mechanisms in corpus cavernosum despite deleterious effects on large myelinated fiber function in rats, and increased phenylephrine-mediated contractions in mouse aorta and rat renal artery. 1, 7, 9, 33 Diabetes blunted mouse penile parasympathetic nitrergic autonomic nerve function; this process also occurs in models where smooth muscle nitric oxide responsiveness is not altered. 7 Similar deficits are observed for nitrergic neurotransmission in gastric fundus of diabetic rats. 34 In diabetic rats, nitrergic nerve innervation goes through a period of reversible dysfunction before eventual apoptotic loss of cell bodies in the major pelvic ganglia. 35 During this reversible period, neuronal-derived nitric oxide may be vulnerable to neutralization by pro-oxidant and inflammatory stresses in diabetes. The beneficial effects of LY2161793 suggest that p38 MAPK may act as a transducer for the cellular stresses that contribute to altered autonomic nitrergic nerve function, at least in conjunction with hyperglycamiadriven activation, as treatment did not alter plasma glucoses in diabetic mice.
Phosphorylated and total levels of p38 MAPK are increased in primary dorsal root ganglion cells from diabetic rats and sural nerve samples from diabetic patients. 3 Furthermore, cultured rat sensory neurons exposed to high levels of glucose and/or oxidative stress revealed increased p38 MAPK activation. Although high glucose-driven activation of p38 alone did not lead to increased cell death of cultured dorsal root ganglion neurons, cell death induced by an exogenous source of oxidative stress (peroxide) was partially prevented by a p38 MAPK inhibitor. 3 Inhibition of p38 also prevented development of motor and sensory nerve conduction deficits in diabetic rats. 9 Although the mechanism of action is not understood, the authors suggested that phosphorylation of transcription factors leading to reduced expression of proteins involved in action potential propagation is plausible. A further possibility would be that restoration of blood flow improves nerve function: the beneficial effects of p38 MAPK inhibition on endothelial function support this notion, which requires further investigation. Diabetes causes an early reduction in autonomic ganglion blood flow in rats; thus, it is possible that relative ischemia might deleteriously affect nitrergic neuronal cell bodies in the major pelvic ganglia. 36 In conclusion, streptozotocin-diabetes causes reduced nitric oxide-mediated endothelium-dependent and -independent smooth muscle responsiveness in corpus cavernosum from MF1 mice. Similarly, nitrergic autonomic nerve function is attenuated. These functional alterations were corrected by LY2161793, suggesting that p38 MAPK activation plays a role in the progression of diabetic erectile neuropathy and vasculopathy.
